Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Finished Goods (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Finished Goods for 5 consecutive years, with $3.7 million as the latest value for Q4 2019.

  • Quarterly Finished Goods rose 446.67% to $3.7 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2019, up 446.67% year-over-year, with the annual reading at $3.7 million for FY2019, 446.67% up from the prior year.
  • Finished Goods hit $3.7 million in Q4 2019 for Aptevo Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $9.1 million in Q4 2015 to a low of $64000.0 in Q2 2018.
  • Historically, Finished Goods has averaged $2.8 million across 5 years, with a median of $1.2 million in 2017.
  • Biggest five-year swings in Finished Goods: plummeted 98.95% in 2018 and later skyrocketed 670.31% in 2019.
  • Year by year, Finished Goods stood at $9.1 million in 2015, then plummeted by 97.83% to $197000.0 in 2016, then surged by 148.73% to $490000.0 in 2017, then soared by 37.76% to $675000.0 in 2018, then soared by 446.67% to $3.7 million in 2019.
  • Business Quant data shows Finished Goods for APVO at $3.7 million in Q4 2019, $1.4 million in Q3 2019, and $493000.0 in Q2 2019.